Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors

Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors

Item
http://www.wikidata.org/entity/Q27701564
Small-Molecule Stabilization of the 14-3-3/Gab2 Protein-Protein Interaction (PPI) InterfaceDiscovery of 4-((3'R,4'S,5'R)-6″-Chloro-4'-(3-chloro-2-fluorophenyl)-1'-ethyl-2″-oxodispiro[cyclohexane-1,2'-pyrrolidine-3',3″-indoline]-5'-carboxamido)bicyclo[2.2.2]octane-1-carboxylic Acid (AA-115/APG-115): A Potent and Orally Active Murine DoubleMDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer.How To Design a Successful p53-MDM2/X Interaction Inhibitor: A Thorough Overview Based on Crystal Structures.Inhibition of the p53/hDM2 protein-protein interaction by cyclometallated iridium(III) compounds.Targeting the MDM2-p53 Protein-Protein Interaction for New Cancer Therapy: Progress and Challenges.Medicinal Chemistry Strategies to Disrupt the p53-MDM2/MDMX Interaction.Protein-protein interaction inhibitors: advances in anticancer drug design.Reviving the guardian of the genome: Small molecule activators of p53.Resistance mechanisms to TP53-MDM2 inhibition identified by in vivo piggyBac transposon mutagenesis screen in an Arf-/- mouse model.Stress-Activated NRF2-MDM2 Cascade Controls Neoplastic Progression in Pancreas.A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma.Bioorthogonal Probes for the Study of MDM2-p53 Inhibitors in Cells and Development of High-Content Screening Assays for Drug Discovery.Understanding Protein-Protein Interactions: Essential Players in (Patho)physiology (Part 1).Targeting MDMX and PKCδ to improve current uveal melanoma therapeutic strategies.Small Molecule Modulators of RING-Type E3 Ligases: MDM and Cullin Families as Targets.Evolution of In Silico Strategies for Protein-Protein Interaction Drug Discovery
P2860

Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors

Item
http://www.wikidata.org/entity/Q27701564
description
2015 nî lūn-bûn
@nan
2015 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Discovery of a Dihydroisoquino ...... linical Trials in p53wt Tumors
@ast
Discovery of a Dihydroisoquino ...... linical Trials in p53wt Tumors
@en
Discovery of a Dihydroisoquino ...... linical Trials in p53wt Tumors
@nl
type
label
Discovery of a Dihydroisoquino ...... linical Trials in p53wt Tumors
@ast
Discovery of a Dihydroisoquino ...... linical Trials in p53wt Tumors
@en
Discovery of a Dihydroisoquino ...... linical Trials in p53wt Tumors
@nl
prefLabel
Discovery of a Dihydroisoquino ...... linical Trials in p53wt Tumors
@ast
Discovery of a Dihydroisoquino ...... linical Trials in p53wt Tumors
@en
Discovery of a Dihydroisoquino ...... linical Trials in p53wt Tumors
@nl
P1433
P1476
P2093
P304
P31
P356
P407
P433
P478
P50
P577
P5875
P698
P921
P356
P1433
P1476
Discovery of a Dihydroisoquino ...... linical Trials in p53wt Tumors
@en
P2093
P304
P31
P356
10.1021/ACS.JMEDCHEM.5B00810
P407
P433
P478
P50
P577
P5875
P698
P921